DETROIT, Mich. – In a move that could change how oncologists treat advanced hormone‑sensitive breast cancer, the U.S. Food and Drug Administration has granted accelerated approval to Etcamah (camizestrant), a once‑daily pill designed for patients whose tumors have spread beyond the breast and rely on estrogen for growth.
Targeted drug paired with early‑detection blood test
Etcamah is intended for a specific group of patients whose cancers lack high levels of the HER2 protein and have developed a genetic alteration in the ESR1 gene. That alteration lets cancer cells keep growing even when estrogen‑blocking drugs are used. The new therapy works in combination with one of three existing CDK4/6 inhibitors, a class of drugs already standard in treating hormone‑sensitive disease.
The approval is tied to a companion diagnostic called Guardant360 CDx. This blood test looks for tiny fragments of tumor DNA circulating in the bloodstream and can identify the ESR1 mutation before imaging studies show tumor progression. Detecting resistance earlier gives doctors and patients a chance to switch therapy before the cancer visibly worsens on a scan.
Clinical trial shows longer time before disease progression
In the pivotal trial, patients who switched to Etcamah after their disease showed the ESR1 change went about 16 months before their cancer worsened, compared with roughly nine months for those who stayed on their original regimen. That translates to roughly seven additional months of disease control for patients who received the new drug.
While the FDA’s decision was based on this improvement in progression‑free time, the agency noted that overall survival data are still pending. AstraZeneca, the drug’s manufacturer, must complete further studies to determine whether Etcamah provides a meaningful clinical benefit in terms of survival.
Safety warnings and usage restrictions
The prescribing information includes a boxed warning about the risk of an irregular heart rhythm. Additional cautions note the potential for an abnormally slow heart rate and a risk of harm to an unborn baby, underscoring the need for careful monitoring.
The approval applies only to patients with advanced disease that meets the specific genetic and hormonal criteria described above, not to all individuals diagnosed with breast cancer.
What this means for patients and providers
The combination of a targeted oral therapy and a blood‑based test represents a shift toward using circulating tumor DNA to guide treatment decisions. For patients whose tumors develop ESR1‑related resistance, the approach could provide an earlier opportunity to move away from a therapy that is no longer effective, potentially preserving quality of life and extending the period of disease control.
Oncologists across the country are expected to incorporate Guardant360 CDx testing into routine monitoring for eligible patients, allowing a more proactive response to emerging resistance. As additional data emerge from AstraZeneca’s required post‑approval studies, the medical community will gain a clearer picture of Etcamah’s long‑term impact on survival and overall outcomes.
Original reporting: WOWO News/Talk (Fort Wayne) — read the source article.
